Lo Coco F, Diverio D, Pandolfi P P, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti M C, Meloni G
University La Sapienza, Rome, Italy.
Lancet. 1992 Dec 12;340(8833):1437-8. doi: 10.1016/0140-6736(92)92625-p.
Acute promyelocytic leukaemia (APL) is characterised by a unique fusion transcript, PML/RAR alpha. We tested for this transcript in 35 APL patients who were in apparent remission after various treatments. 11 of 13 patients who tested positive 4 months after achieving remission were in relapse 1-4 months later. All 22 patients who tested negative at 4 months were disease-free after a further 3 months to five years. The test may therefore prove useful in determining the need for additional treatment during clinical remission.
急性早幼粒细胞白血病（APL）的特征是存在一种独特的融合转录本，即早幼粒细胞白血病蛋白/维甲酸受体α（PML/RARα）。我们对35例经各种治疗后处于明显缓解期的APL患者进行了该转录本检测。在缓解后4个月检测呈阳性的13例患者中，有11例在1至4个月后复发。4个月时检测呈阴性的所有22例患者在接下来的3个月至5年中均无疾病。因此，该检测可能有助于确定临床缓解期是否需要额外治疗。
